Patents by Inventor Futoshi Hasegawa

Futoshi Hasegawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10807945
    Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: October 20, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
  • Publication number: 20200317623
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Application
    Filed: January 7, 2020
    Publication date: October 8, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji HORI, Futoshi HASEGAWA, Daisuke URABE, Hirotaka KUREBAYASHI
  • Publication number: 20200149644
    Abstract: A reciprocating body (2) has valve element (6) including deflecting surface (10a), valve shaft (7) guided by guide cylinder (4), and packing (8) having an annular shape circularly brought into close contact with valve seat (12a) in a state where the reciprocating body (2) is in a closed position. The valve element (6) includes large diameter portion (9a), and small diameter portion (9b) and deflecting portion (10). The large diameter portion (9a) has flange surface (9d) supporting the packing (8) in a state where the packing (8) is exposed to the primary flow passage side. The flange surface (9d) is formed such that the flange surface (9d) is allowed to come into contact with the valve seat (12a) via the packing (8). Recess (9c) is formed on the outer periphery of the small diameter portion (9b), and a portion of the packing (8) is fitted in the recess (9c).
    Type: Application
    Filed: January 14, 2020
    Publication date: May 14, 2020
    Applicant: IISHIZAKI Co., LTD.
    Inventors: Nobuyuki Ishizaki, Takeshi Ouchi, Daisuke Kikuchi, Kazuhiko Kojima, Futoshi Hasegawa, Kohei Mizutani
  • Patent number: 10562861
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: February 18, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Publication number: 20190390172
    Abstract: The present invention provides a compound of formula (1) or a salt thereof wherein ring Q1 is optionally-substituted C6-10 aryl, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is C1-4 alkylene which may be optionally substituted with 1 to 3 fluorine atoms or C3-7 cycloalkyl; W2 is —NR4aC(O)—, etc. wherein R4a is hydrogen atom or C1-6 alkyl; ring Q2 is optionally-substituted C6-10 aryl, etc., which has an inhibitory effect on the sphere-forming ability of cancer cells and is useful an agent for removing iPS cells.
    Type: Application
    Filed: December 19, 2017
    Publication date: December 26, 2019
    Inventors: Yasushi Hiramine, Masayo Fujiwara, Hitoshi Ban, Futoshi Hasegawa
  • Patent number: 10458161
    Abstract: An inside handle support member for a vehicle door includes: a base member that is a frame having an opened vehicle interior side end portion, in which the base member is detachably mounted to a trim constituting a vehicle interior side surface of the vehicle door through an aperture formed in the trim, and rotatably supports an inside handle configured to operate a lock device provided in the vehicle door; and a bezel that is a frame detachably mounted to a peripheral edge of the vehicle interior side end portion of the base member, in which the bezel includes: an engagement hole; and an engagement hole forming portion that defines a vehicle exterior side edge of the engagement hole, and the base member includes: an engagement claw protruding on an outer peripheral surface of the base member; and a guide protrusion having a guide surface.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: October 29, 2019
    Assignee: AISIN SEIKI KABUSHIKI KAISHA
    Inventors: Yukinobu Kunimatsu, Atsushi Kamiya, Yuusaku Miki, Masamichi Morita, Haruyasu Hasegawa, Futoshi Harada
  • Patent number: 10294237
    Abstract: The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)—, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: May 21, 2019
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Manabu Kusagi, Yosuke Takanashi, Futoshi Hasegawa
  • Publication number: 20190119220
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Application
    Filed: October 23, 2018
    Publication date: April 25, 2019
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Patent number: 10150743
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: December 11, 2018
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Publication number: 20180230085
    Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Application
    Filed: June 21, 2016
    Publication date: August 16, 2018
    Inventors: Hitoshi Ban, Manabu Watanabe, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
  • Publication number: 20180194773
    Abstract: The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)—, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Application
    Filed: June 21, 2016
    Publication date: July 12, 2018
    Inventors: Hitoshi Ban, Manabu Kusagi, Yosuke Takanashi, Futoshi Hasegawa
  • Patent number: 9828362
    Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 28, 2017
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
  • Publication number: 20170166552
    Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Inventors: Hitoshi Ban, Manabu Watanabe, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
  • Publication number: 20160251319
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Application
    Filed: May 11, 2016
    Publication date: September 1, 2016
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., Astrazeneca Aktiebolag
    Inventors: Seiji HORI, Futoshi HASEGAWA, Daisuke URABE, Hirotaka KUREBAYASHI
  • Patent number: 9376398
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: June 28, 2016
    Assignees: Sumitomo Dainippon Pharma Co., LTD, Astrazeneca Aktiebolag
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Publication number: 20150099770
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Application
    Filed: May 17, 2013
    Publication date: April 9, 2015
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Publication number: 20130116227
    Abstract: Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R1 is a substitutable aminosulfonyl group, etc.; R2 is a hydrogen atom, etc.; R3 is a hydrogen atom, etc.; R4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R5a, R5b and R5c are each independently hydrogen atoms, etc.; R6 is a halogen atom, a cyano group, etc.; R7 and R8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.
    Type: Application
    Filed: July 12, 2011
    Publication date: May 9, 2013
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Seiji Katayama, Seiji Hori, Futoshi Hasegawa, Kuniko Suzuki